ArticleOncotarget2016
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Andrea Ghelli Luserna Di Rorà et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this papertrialcites it